Drug Profile
OXB 302
Alternative Names: 5T4-CAR T-cell therapeutics - Oxford Biomedica; 5T4-specific CAR T-cells; Anti-5T4 CAR T cells; OXB-302Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (Parenteral)
- 22 Sep 2021 Preclinical development is ongoing United Kingdom
- 22 Sep 2021 Preclinical trials in Solid tumours in United Kingdom (Parenteral) before September 2021